Microbiota and metabolites alterations in proximal and distal gastric cancer patients

Yan Yang, Daofeng Dai, Wen Jin, Yingying Huang, Yingzi Zhang, Yiran Chen, Wankun Wang, Lin Wu, Xiangliu Chen, Jing Zhang, Haohao Wang, Haibin Zhang, Lisong TengJournal of Translational Medicine 2022 · DOI

Abstract

First, the differences in microbial composition and metabolites between the proximal and distal gastric cancers were described; then, the correlation between microbiota and metabolites was preliminarily discussed. These microbes and metabolites deserve further investigations as they may reveal the different mechanisms involved in the occurrence and development of proximal and distal gastric cancers and provide a basis for future treatments.

Introduction

Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. It is broadly categorized by location: proximal (the upper part of the stomach near the esophagus) and distal (the lower part). These two types exhibit different clinical behaviors, biological markers, and patient outcomes; proximal GC generally carries a worse prognosis. While the role of the gut microbiome in cancer is well-established, the specific differences in microbial composition and metabolic activity between these two anatomical sites remain poorly understood. This study investigates whether the microbial and metabolic profiles differ significantly between proximal and distal tumors, potentially offering new avenues for site-specific treatments.

Methods

The researchers employed a multi-omics approach on tissue samples from 29 patients (13 proximal, 16 distal). Microbiome profiling was conducted using 16S rRNA amplicon sequencing (targeting the V3-V4 regions) to identify bacterial taxa in tumor tissues (T) and matched non-tumor tissues (N). Untargeted metabolomics was performed using Ultra-High Performance Liquid Chromatography-Mass Spectrometry (UHPLC-MS/MS) to detect small molecules within the tissues. Integrated analysis using Spearman correlation linked specific bacterial genera with differential metabolites. Statistical modeling, including Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA), was used to identify discriminative metabolites.

Results

Microbial Diversity and Composition

The study found that microbial diversity, as measured by the Shannon index, was significantly higher in tumor tissues compared to their respective normal tissues for both proximal and distal sites. However, there was no significant difference in diversity between the proximal and distal tumor tissues themselves.

Shannon index comparing microbial diversity across proximal and distal tumor and normal tissues.

At the phylum level, the overall composition remained relatively consistent across the groups, though specific shifts were observed.

Relative abundance of microbial phyla across distal and proximal tissue groups.

Key taxonomic shifts included the enrichment of Rikenellaceae_RC9_gut_group, Porphyromonas, and Catonella in proximal tumors, while distal tumors were characterized by an increase in Methylobacterium-Methylorubrum. Notably, Helicobacter pylori abundance decreased in tumor tissues at both sites, suggesting a shift in the microenvironment that favors other opportunistic bacteria.

Metabolic Profiling

Metabolomics revealed a higher degree of metabolic volatility in the distal region, with 30 discriminative metabolites identified between distal tumor and normal tissue, compared to only 4 in the proximal region. Distal GC was heavily associated with amino acid metabolism (arginine, alanine, aspartate, glutamate) and the sphingolipid signaling pathway. In contrast, proximal GC metabolites were more closely linked to hormone metabolism.

Discussion and Conclusion

This study demonstrates that proximal and distal gastric cancers possess unique biological "fingerprints." The identification of site-specific microbial and metabolic shifts—notably the enrichment of Methylobacterium in distal tumors and Rikenellaceae in proximal ones—correlates with distinct cancer-promoting pathways. These findings suggest that the progression of GC at different anatomical sites may be driven by different mechanisms.

While the study provides valuable insights, limitations include a small sample size and the correlative nature of the data. Future work is required to establish causal relationships and explore the potential for targeted microbial or metabolic therapies in treating site-specific gastric cancer.

Summary updated

Abstract

First, the differences in microbial composition and metabolites between the proximal and distal gastric cancers were described; then, the correlation between microbiota and metabolites was preliminarily discussed. These microbes and metabolites deserve further investigations as they may reveal the different mechanisms involved in the occurrence and development of proximal and distal gastric cancers and provide a basis for future treatments.
BibTeX
@article{yang2022microbiota,
  author = {Yan Yang and Daofeng Dai and Wen Jin and Yingying Huang and Yingzi Zhang and Yiran Chen and Wankun Wang and Lin Wu and Xiangliu Chen and Jing Zhang and Haohao Wang and Haibin Zhang and Lisong Teng},
  title = {{Microbiota and metabolites alterations in proximal and distal gastric cancer patients}},
  journal = {Journal of Translational Medicine},
  year = {2022},
  doi = {10.1186/s12967-022-03650-x},
}
Figure